Preparation method and application of cis-2, 3-disubstituted indoline compound

By synthesizing and isolating cis-2,3-disubstituted indoline compounds, the problem of insufficient research on this type of compound in the existing technology has been solved, and effective inhibition of tumor cells such as colorectal cancer and esophageal cancer has been achieved, providing new opportunities for drug development.

CN118878451AInactive Publication Date: 2024-11-01ZHENGZHOU UNIV
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202410914293.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-09
Publication Date
2024-11-01
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

There is limited research on 2,3-disubstituted indoline compounds in the current technology, especially the cis configuration compounds. Their changes in biological activity have not been fully explored, and their applications in the treatment of atherosclerosis, cardiovascular diseases, anxiety, and depression have not been fully developed.

Method used

A specific cis-2,3-disubstituted indoline compound was synthesized by reacting N,3-disubstituted indoles with the corresponding aldehydes or ketones under ultraviolet light using tetrabutylammonium decatungstate (TBADT) as a catalyst to generate compounds with the cis configuration, which were then purified by column chromatography.

Benefits of technology

A cis-2,3-disubstituted indoline compound with potential antitumor activity was prepared, showing significant inhibitory effects on tumor cells such as colorectal cancer and esophageal cancer, providing a new direction for drug development.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118878451A_ABST
    Figure CN118878451A_ABST
Patent Text Reader

Abstract

The invention relates to an anti-tumor cis-2, 3-disubstituted indoline compound and a synthesis method thereof in the technical field of medicines, and belongs to the technical field of chemical pharmacy. In particular to a cis-2, 3-disubstituted indoline compound as shown in a formula I and application of the cis-2, 3-disubstituted indoline compound in preparation of antitumor drugs. The structural general formula of the cis-2, 3-disubstituted indoline compound is as shown in formula I in the specification. The cis-2, 3-disubstituted indoline compound is generated by reacting 3-substituted-N-acylindole with a substrate in the presence of tetrabutylammonium decatungstate (TBADT) serving as a photocatalyst. The cis-2, 3-disubstituted indoline compound shown in the formula I has the biological activity of inhibiting tumor cell proliferation and can be used for preparing antitumor drugs. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medical technology, and specifically relates to a preparation method and use of a class of cis-2,3-disubstituted indoline compounds. Background Art

[0002] Indoline structures are commonly found in drug molecules and natural products with biological activity. Indoline compounds are widely used in drugs, dyes, pesticides and materials science. For example, vincristine and vinblastine have antibacterial and antitumor activities. Vinblastine has antitumor, antihypertensive, hypoglycemic and diuretic effects. The synthesis of indoline compounds with novel structures and the study of their biological activities have always been a hot frontier.

[0003] At present, the indoline derivatives that have been studied more include oxidized indole, spirocyclic indoline, 2,3-unsubstituted indoline and 2,3-cyclized indoline. However, there are few studies on 2,3-disubstituted open-ring indoline. In previous studies, it was found that 2,3 dialkyl-substituted indoline has the activity of inhibiting cholesterol ester transfer protein (CETP) and can be used to treat atherosclerosis and cardiovascular (WO2006032987A1). 2-Acyl-3-alkyl-substituted indoline has the function of treating anxiety and depression (JP2008019173A). We previously studied the synthesis and anti-tumor activity of trans-2,3-disubstituted indoline and found that this type of compound has a certain inhibitory activity on the proliferation of colorectal cancer and esophageal cancer cells (2023113072609).

[0004] Since the change of the three-dimensional structure of the compound will have a great influence on its biological activity, if the trans-2,3-disubstituted indoline is converted to the cis configuration, its biological activity may change significantly. Therefore, it is necessary to conduct synthesis and biological activity research on cis-2,3-disubstituted indoline compounds. Summary of the invention

[0005] The object of the present invention is to provide a cis-2,3-disubstituted indoline compound having a structure of formula I and a preparation method and use thereof.

[0006] The present invention provides a cis-2,3-disubstituted indoline compound as shown in Formula I, characterized in that the 2,3-disubstituted indoline compound has a cis-configuration and has the following general structural formula:

[0007]

[0008] Among them: R 1 For cyano, C 1-8 Alkanoyl, aroyl, sulfonyl, C 1-8 Alkoxyacyl, aryloxyacyl, aminoacyl, arylaminoacyl or C 1-8Alkyl; R 2 C 1-8 Alkyl, C 1-8 Cycloalkyl, C 1-8 Alkanoyl, aroyl, substituted aroyl, sulfonyl, C 1-8 Alkoxyacyl, aryloxyacyl, aminoacyl, arylaminoacyl or C 1-8 Alkyl; R 3 C 1-8 Alkanoyl, aroyl, sulfonyl, C 1-8 Alkoxyacyl, aryloxyacyl, aminoacyl, arylaminoacyl or C 1-8 Alkyl; R 4 For hydrogen, deuterium, halogen, cyano, C 1-8 Alkyl, aryl, heteroaryl, C 1-8 Alkanoyl, aroyl, sulfonyl, C 1-8 Alkoxyacyl, aryloxyacyl, aminoacyl, arylaminoacyl or C 1-8 Alkyl.

[0009] 2. The compound of formula I, or a pharmaceutically acceptable salt or hydrolyzable ester thereof as claimed in claim 1, wherein the 2-position and 3-position of indoline in the compound of formula I are both substituted, and the two substituents are in relative cis positions.

[0010] 3. The pharmaceutically acceptable salt of the cis-2,3-disubstituted indoline compound according to claim 1 comprises potassium salt, sodium salt, ammonium salt, magnesium salt, calcium salt or hydrochloride.

[0011] 4. The compound of formula I and the pharmaceutically acceptable salt thereof according to claim 1, characterized in that, in the compound of formula I, both the 2-position and the 3-position of indoline have substituents, and the two substituents are in relative cis positions. Including but not limited to the following compounds:

[0012]

[0013] 5. The method for preparing the cis-2,3-disubstituted indoline compound according to claim 1-4, characterized in that the method comprises the following steps:

[0014]

[0015] Step 1: At room temperature, in a reaction tube, N,3-disubstituted indole (Formula II, 1.0 equivalent) and HR 2(1.3 equivalents) and 2% mol of tetrabutylammonium decatungstate (TBADT) catalyst are dissolved in dichloromethane / acetonitrile (5 ml of mixed solvent is added for every 1 mmol of substrate; v / v, 1 / 1), and the air in the reaction tube is replaced with nitrogen or argon. The reaction solution is pumped into a serpentine reaction tube with a peristaltic pump in a nitrogen or argon atmosphere and irradiated with 40 watts of 390nm purple light for 24 hours. In this step, the solvent can also be acetonitrile, acetone, 1,2-dichloroethane, dichloromethane, chloroform, ethyl acetate, or a mixed solvent of two of them. In this step, the wavelength of the light used can be any wavelength or band from 365nm to 450nm. In this step, the reaction can also be carried out in a glass or quartz reaction tube, but the reaction efficiency will be reduced and obvious trans byproducts will be generated.

[0016] Step 2: After the reaction is completed, the reaction solution is concentrated and separated by column chromatography to obtain the target compound 1-30.

[0017] 6. A pharmaceutical composition, characterized in that it comprises the compound of formula I according to any one of claims 1 to 4, a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, excipient or other active drug.

[0018] 7. Use of the compound of formula I according to any one of claims 1 to 4, a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 5 in the preparation of a drug for treating and / or preventing cancer.

[0019] 8. The use according to claim 7, characterized in that the cancer includes malignant melanoma, glioma, lung cancer, prostate cancer, breast cancer, myeloproliferative and lymphoproliferative diseases, gastric cancer, colorectal cancer, esophageal cancer, ovarian cancer, and cervical cancer. Specific implementation methods

[0021] The present invention is further described in detail in conjunction with the following specific examples, and the protection content of the present invention is not limited to the following examples. Without departing from the spirit and scope of the inventive concept, the changes and advantages that can be thought of by those skilled in the art are included in the present invention, and the attached claims are the scope of protection. The process, conditions, reagents, experimental methods, etc. for implementing the present invention, except for the contents specifically mentioned below, are all common knowledge and common common sense in the art, and the present invention has no special restrictions. The raw materials used in the following examples are all commercially available analytically pure chemicals.

[0022] In the preparation method of the present invention, the preparation process of the raw material compound of formula II is: 3-substituted indole is subjected to condensation reaction with acid anhydride or acid chloride. The specific synthesis method can be found in document (1) ACS Catal. 2021, 11, 998-1007; document (2) COMMUNICATIONS CHEMISTRY 2021 4:2; and document (3) Chem. Eur. J. 2022, 28, e202201707.

[0023] The raw material used in the preparation method of the present invention is HR 2 The compounds were commercially available analytically pure chemicals or prepared according to the prior art.

[0024] The preparation method of the TBADT catalyst used in the preparation method of the present invention can be found in the literature: Nature 2018, 560, 70.

[0025] The lamp used in the preparation method of the present invention is a purple lamp with a wavelength of 390nm. Any wavelength or waveband between 365-400nm can also be used.

[0026] The serpentine reaction tube used in the preparation method of the present invention is made of quartz material. A glass or quartz Schlenk tube can also be used, but the reaction efficiency and product yield will be reduced.

[0027] The inert gas used in the preparation method of the present invention is nitrogen, and argon can also be used.

[0028] The preferred solvent used in the preparation method of the present invention is dichloromethane / acetonitrile (1 / 1, v / v), and can also be acetonitrile, acetone, 1,2-dichloroethane, dichloromethane, chloroform, ethyl acetate or a mixed solvent of any two thereof.

[0029] Example 1: Compound 1 (Formula I, R 1 =Cyano, R 2 =4-methylbenzoyl, R 3 = tert-butyloxycarbonyl, R 4 =H) preparation.

[0030]

[0031] N-Boc-3-cyanoindole (0.2mmol, 48mg), p-methylbenzaldehyde (0.26mmol, 31ul) and photocatalyst TBADT (0.004mmol, 13mg) and 2mL MeCN / DCM (v / v, 1 / 1) were added to a 10ml dry Schlenk tube in sequence. The mixture was degassed and filled with nitrogen, and the reaction solution was pumped into a serpentine reactor. The reaction solution was irradiated with a 30W purple lamp for 24 hours. After the reaction was completed, it was concentrated on a rotary evaporator and then separated by column chromatography to obtain 58mg of white solid compound 1 with a yield of 81%. 1 H NMR(400MHz, CDCl3)δ7.92–7.80(m,3H),7.48(d,J=8.3Hz,0.3H),7.28–7.18(m,4H),6.97(t,J=7.6Hz,1H),5.9 8(d,J=11.2Hz,0.3H),5.85(d,J=11.3Hz,0.7H),4.73(d,J=11.1Hz,1H),2.35(s,3H),1.49(s,3H),1.22(s,6H). 13 C NMR(101MHz,Chloroform-d)δ193.3,150.7,145.4,145.3,142.7,132.7,132.5,130.4,129.8,129.0,128.8.0,1 24.8,124.5,123.4,122.6,116.3,115.1,83.4,82.5,62.6,62.3,34.5,33.9,28.3,28.0,21.9.HRMS(ESI)calcd for[C 22 H 22 N2O3+Na] + :385.1523, found 385.1520.

[0032] Example 2: Compound 2 (Formula I, R 1 =Cyano, R 2 =4-methoxybenzoyl, R 3 = tert-butyloxycarbonyl, R 4 =H) preparation.

[0033]

[0034] N-Boc-3-cyanoindole (0.2mmol, 48mg), p-methoxybenzaldehyde (0.26mmol, 31ul) and photocatalyst TBADT (0.004mmol, 13mg) and 2mL MeCN / DCM (v / v, 1 / 1) were added to a 10ml dry Schlenk tube in sequence. The mixture was degassed and filled with nitrogen, and the reaction solution was pumped into a serpentine reactor. The reaction solution was irradiated with a 30W purple lamp for 24 hours. After the reaction was completed, it was concentrated on a rotary evaporator and then separated by column chromatography to obtain 47mg of colorless oily compound 2 with a yield of 63%. 1 HNMR(400MHz,Chloroform-d)δ8.00(dd,J=16.0,8.0Hz,2.7H),7.56(d,J=8.0Hz,0.3H),7.35–7.28(m,2H),7.04(t,J=7.5Hz,1H),6.9 8(d,J=8.6Hz,2H),6.04(d,J=11.2Hz,0.3H),5.91(d,J=11.2Hz,0.7H),4.81(d,J=11.3Hz,1H),3.87(s,3H),1.57(s,3H),1.29(s,6H). 13 C NMR(101MHz,Chloroform-d)δ192.0,164.5,150.7,150.7,142.8,131.3,131.0,130.4,130.3,127.9,124 .8,124.5,123.3,122.7,116.4,115.1,114.4,82.5,62.5,62.1,55.6,34.6,28.4,28.1.HRMS(ESI)calcd for[C 22 H 22 N2O4+Na] + :401.1472found401.1470.

[0035] Example 3: Compound 3 (Formula I, R 1 =Cyano, R 2 =3,5-dimethoxybenzoyl, R 3 = tert-butyloxycarbonyl, R 4 =H) preparation.

[0036]

[0037] N-Boc-3-cyanoindole (0.2mmol, 48mg), 3,5-dimethoxybenzaldehyde (0.26mmol, 43mg), photocatalyst TBADT (0.004mmol, 13mg) and 2mL MeCN / DCM (v / v, 1 / 1) were added to a 10ml dry Schlenk tube in sequence. The mixture was degassed and filled with nitrogen, and the reaction solution was pumped into a serpentine reactor. The reaction solution was irradiated with a 30W purple lamp for 24 hours. After the reaction was completed, it was concentrated on a rotary evaporator and then separated by column chromatography to obtain 50mg of colorless oily compound 3 with a yield of 62%. 1 H NMR(400MHz,Chloroform-d)δ7.99(d,J=8.2Hz,0.67H),7.56(d,J=7.3Hz,0.35H),7.35(dd,J=18.1,7.9Hz,2H),7.18–7.03(m,3H) ,6.71(s,1H),6.00(d,J=11.1Hz,0.3H),5.86(d,J=11.3Hz,0.7H),4.82(d,J=11.2Hz,1H),3.82(s,6H),1.58(s,3H),1.33(s,6H). 13 C NMR(101MHz,Chloroform-d)δ193.5,161.2,142.7,136.8,130.6,124.6,123.5,122.5,116 .1,115.2,106.7,106.5,106.4,83.5,82.8,63.1,55.8,34.6,28.4,28.1.HRMS(ESI)calcd for[C 23 H 24 N2O5+Na] + :431.1577 found 431.1578.

[0038] Example 4: Compound 4 (Formula I, R 1 =Cyano, R 2 =4-bromobenzoyl, R 3 = tert-butyloxycarbonyl, R 4 =H) preparation.

[0039]

[0040] N-Boc-3-cyanoindole (0.2mmol, 48mg), 4-bromobenzaldehyde (0.26mmol, 48mg) and photocatalyst TBADT (0.004mmol, 13mg) and 2mL MeCN / DCM (v / v, 1 / 1) were added to a 10ml dry Schlenk tube in sequence. The mixture was degassed and filled with nitrogen, and the reaction solution was pumped into a serpentine reactor. The reaction solution was irradiated with a 30W purple lamp for 24 hours. After the reaction was completed, it was concentrated on a rotary evaporator and then separated by column chromatography to obtain 67mg of white solid compound 4 with a yield of 79%. 1 H NMR(400MHz,Chloroform-d)δ8.06–7.83(m,3H),7.67(d,J=8.1Hz,2H),7.34(dd,J=18.9,4.9Hz,2H),7.08(t,J=7 .5Hz,1H),6.00(d,J=11.1Hz,0.3H),5.87(d,J=11.3Hz,5.8H),4.82(d,J=11.7Hz,1H),1.57(s,3H),1.30(s,6H). 13 C NMR(101MHz,Chloroform-d)δ193.1,142.5,141.5,133.7,132.6,132.5,130.6,130.5,130.3,130.1,129.9,124.9 ,124.6,124.6,123.6,123.5,122.3,115.2,115.1,82.9,62.8,62.4,34.4,33.7,29.8,28.4,28.1.HRMS(ESI)calcd for[C 21 H 19 BrN2O3+Na] + :449.0472found449.0474.

[0041] Example 5: Compound 5 (Formula I, R 1 =Cyano, R 2 =4-chlorobenzoyl, R 3 = tert-butyloxycarbonyl, R 4 =H) preparation.

[0042]

[0043] N-Boc-3-cyanoindole (0.2mmol, 48mg), 4-chlorobenzaldehyde (0.26mmol, 36mg) and photocatalyst TBADT (0.004mmol, 13mg) and 2mL MeCN / DCM (v / v, 1 / 1) were added to a 10ml dry Schlenk tube in sequence. The mixture was degassed and filled with nitrogen, and the reaction solution was pumped into a serpentine reactor. The reaction solution was irradiated with a 30W purple lamp for 24 hours. After the reaction was completed, it was concentrated on a rotary evaporator and then separated by column chromatography to obtain 66mg of white solid compound 5 with a yield of 87%. 1 H NMR(400MHz,Chloroform-d)δ8.06–7.88(m,3H),7.50(d,J=8.1Hz,2H),7.34(dd,J=15.9,7.7Hz,2H),7.08(t,J =7.6Hz,1H),6.01(d,J=11.0Hz,0H),5.88(d,J=11.3Hz,1H),4.81(t,J=12.5Hz,1H),1.57(s,3H),1.30(s,5H). 13 C NMR(101MHz,Chloroform-d)δ192.8,150.5,141.1,133.4,130.7,130.5,130.3,130.1,129.6,129.5,124 .6,123.6,123.5,122.3,116.2,115.3,115.2,83.7,82.9,62.9,62.4,34.5,28.4,28.1.HRMS(ESI)calcd for[C 21 H 19 ClN2O3+Na] + :405.0976,found 405.0976.

[0044] Example 6: Compound 6 (Formula I, R 1 =Cyano, R 2 =4-fluorobenzoyl, R 3 = tert-butyloxycarbonyl, R 4 =H) preparation.

[0045]

[0046] N-Boc-3-cyanoindole (0.2mmol, 48mg), 4-fluorobenzaldehyde (0.26mmol, 31mg) and photocatalyst TBADT (0.004mmol, 13mg) and 2mL MeCN / DCM (v / v, 1 / 1) were added to a 10ml dry Schlenk tube in sequence. The mixture was degassed and filled with nitrogen, and the reaction solution was pumped into a serpentine reactor. The reaction solution was irradiated with a 30W purple lamp for 24 hours. After the reaction was completed, it was concentrated on a rotary evaporator and then separated by column chromatography to obtain 42mg of colorless oily compound 6 with a yield of 58%. 1 H NMR(400MHz,Chloroform-d)δ8.08–7.98(m,2.7H),7.56(d,J=8.2Hz,0.3H),7.38–7.21(m,2H),7.20(t,J=8.4Hz,2H),7.0 7(t,J=7.6Hz,1H),6.02(d,J=11.0Hz,0.3H),5.89(d,J=11.3Hz,0.6H),4.81(t,J=12.0Hz,1H),1.57(s,3H),1.30(s,6H). 13 CNMR(101MHz,Chloroform-d)δ192.4,150.6,142.6,131.7,131.6,131.5,131.4,130.6,130.5,124.9,124.5,123.6,12 3.5,122.4,116.6,116.5,116.4,116.3,116.2,115.2,83.7,82.8,62.8,62.4,34.5,33.8,28.4,28.1.HRMS(ESI)calcd for[C 21 H 19 FN2O3+Na] + :389.1272, found 389.1269.

[0047] Example 7: Compound 7 (Formula I, R 1 =Cyano, R 2 =2-naphthoyl, R 3 = tert-butyloxycarbonyl, R 4 =H) preparation.

[0048]

[0049] N-Boc-3-cyanoindole (0.2mmol, 48mg), 2-naphthaldehyde (0.26mmol, 41mg) and photocatalyst TBADT (0.004mmol, 13mg) and 2mL MeCN / DCM (v / v, 1 / 1) were added to a 10ml dry Schlenk tube in sequence. The mixture was degassed and filled with nitrogen, and the reaction solution was pumped into a serpentine reactor. The reaction solution was irradiated with a 30W purple lamp for 24 hours. After the reaction was completed, it was concentrated on a rotary evaporator and then separated by column chromatography to obtain 40mg of colorless oily compound 7 with a yield of 50%. 1 H NMR(400MHz,Chloroform-d)δ8.56(d,J=30.7Hz,1H),8.11–7.85(m,5H),7.68–7.56(m,2H),7.35(dd,J=18.0,7.5Hz,2H),7 .08(t,J=7.5Hz,1H),6.27(d,J=11.0Hz,0.3H),6.14(d,J=11.2Hz,0.7H),4.90(d,J=11.4Hz,1H),1.59(s,3H),1.29(s,6H). 13 CNMR(101MHz,Chloroform-d)δ193.7,150.7,142.8,136.2,132.5,130.5,129.9,129.3,129.3,128.0,127 .3,127.1,124.5,124.1,123.5,123.4,122.6,116.3,115.2,82.7,62.8,34.7,28.4,28.1.HRMS(ESI)calcd for[C 25 H 22 N2O3+Na] + :421.1523,found421.1526.

[0050] Example 8: Compound 8 (Formula I, R 1 =Cyano, R 2 =4-phenylbenzoyl, R 3 = tert-butyloxycarbonyl, R 4 =H) preparation.

[0051]

[0052] N-Boc-3-cyanoindole (0.2mmol, 48mg), 4-phenylbenzaldehyde (0.26mmol, 47mg) and photocatalyst TBADT (0.004mmol, 13mg) and 2mL MeCN / DCM (v / v, 1 / 1) were added to a 10ml dry Schlenk tube in sequence. The mixture was degassed and filled with nitrogen, and the reaction solution was pumped into a serpentine reactor. The reaction solution was irradiated with a 30W purple lamp for 24 hours. After the reaction was completed, it was concentrated on a rotary evaporator and then separated by column chromatography to obtain 48mg of colorless oily compound 8 with a yield of 57%. 1 H NMR(400MHz,Chloroform-d)δ8.14–8.01(m,2H),7.75(d,J=7.8Hz,2H),7.65(d,J=7.6Hz,2H),7.53–7.30(m,6H),7.08( t,J=7.5Hz,1H),6.12(d,J=11.1Hz,0.3H),5.99(d,J=11.3Hz,0.7H),4.87(d,J=11.1Hz,1H),1.59(s,3H),1.33(s,6H). 13 CNMR(101MHz,Chloroform-d)δ193.4,146.9,142.7,139.5,133.7,130.5,130.4,129.5,129.3,129.1,128.6,127.7 ,127.4,124.9,124.5,123.5,122.6,116.3,115.2,83.6,82.7,62.8,62.4,34.6,33.9,28.4,28.1.HRMS(ESI)calcd for[C 27 H 24 FN2O3+Na] + :447.1679,Found447.1677.

[0053] Example 9: Compound 9 (Formula I, R 1 =Cyano, R 2 =3-phenoxybenzoyl, R 3 = tert-butyloxycarbonyl, R 4 =H) preparation.

[0054]

[0055] N-Boc-3-cyanoindole (0.2mmol, 48mg), 3-phenoxybenzaldehyde (0.26mmol, 51mg) and photocatalyst TBADT (0.004mmol, 13mg) and 2mL MeCN / DCM (v / v, 1 / 1) were added to a 10ml dry Schlenk tube in sequence. The mixture was degassed and filled with nitrogen, and the reaction solution was pumped into a serpentine reactor. The reaction solution was irradiated with a 30W purple lamp for 24 hours. After the reaction was completed, it was concentrated on a rotary evaporator and then separated by column chromatography to obtain 48mg of colorless oily compound 9 with a yield of 55%. 1 HNMR(400MHz,Chloroform-d)δ7.97(d,J=8.2Hz,1H),7.79–7.58(m,2H),7.49(t,J=8.0Hz,1H),7.40–7.29(m,5H),7.15(t,J=7.6 Hz,1H),7.09–7.02(m,3H),6.00(d,J=8.7Hz,0.3H),5.86(d,J=10.8Hz,0.7H),4.80(d,J=10.9Hz,1H),1.58(s,3H),1.32(s,6H). 13 C NMR(101MHz,Chloroform-d)δ158.1,156.4,142.5,136.6,130.5,130.1,124.5,124.3,124.2,123.5,123.4,123.2, 119.4,119.3,119.3,118.6,118.4,116.1,115.2,115.1,82.7,63.0,62.6,34.4,33.8,28.4,28.1.HRMS(ESI)calcd for[C27H24N2O4+Na] + :463.1628,Found 463.1630.

[0056] Example 10: Compound 10 (Formula I, R 1 =Cyano, R 2 =4-methoxybenzoyl, R 3 = tert-butyloxycarbonyl, R 4 =H) preparation.

[0057]

[0058] N-Boc-3-cyanoindole (0.2mmol, 48mg), methyl 4-formylbenzoate (0.26mmol, 43mg), photocatalyst TBADT (0.004mmol, 13mg) and 2mL MeCN / DCM (v / v, 1 / 1) were added to a 10ml dry Schlenk tube in sequence. The mixture was degassed and filled with nitrogen, and the reaction solution was pumped into a serpentine reactor. The reaction solution was irradiated with a 30W purple lamp for 24 hours. After the reaction was completed, it was concentrated on a rotary evaporator and then separated by column chromatography to obtain 41mg of colorless oily compound 10 with a yield of 51%. 1 H NMR(400MHz,Chloroform-d)δ8.18(d,J=8.1Hz,2H),8.03(d,J=17.6Hz,2.7H),7.56(s,br,0.3H),7.31–7.26(m,2H),7.09(t,J =7.5Hz,1H),6.04(d,J=11.5Hz,0.3H),5.93(d,J=11.1Hz,1H),4.85(d,J=10.8Hz,1H),3.96(s,3H),1.57(s,3H),1.30(s,6H). 13 C NMR(101MHz,Chloroform-d)δ193.7,166.1,135.0,130.3,128.7,124.6,123.7,116.1,115.4,52.7,34.5,28.1.HRMS(ESI)calcd for[C23H22N5O5+Na] + :429.1421,found:429.1424.

[0059] Example 11: Compound 11 (Formula I, R 1 =Cyano, R 2 =3-methoxybenzoyl, R 3 = tert-butyloxycarbonyl, R 4 =H) preparation.

[0060]

[0061] N-Boc-3-cyanoindole (0.2mmol, 48mg), methyl 3-formylbenzoate (0.26mmol, 43mg), photocatalyst TBADT (0.004mmol, 13mg) and 2mL MeCN / DCM (v / v, 1 / 1) were added to a 10ml dry Schlenk tube in sequence. The mixture was degassed and filled with nitrogen, and the reaction solution was pumped into a serpentine reactor. The reaction solution was irradiated with a 30W purple lamp for 24 hours. After the reaction was completed, it was concentrated on a rotary evaporator and then separated by column chromatography to obtain 50mg of colorless oily compound 11 with a yield of 62%. 1 H NMR(400MHz,Chloroform-d)δ8.63(s,1H),8.31(d,J=7.8Hz,1H),8.21(d,J=7.7Hz,1H),8.00(d,J=8.2Hz,1H),7.63(t,J=7.6Hz,1H),7.41– 7.28(m,2H),7.08(t,J=7.5Hz,1H),6.10(s,0.3H),6.00(d,J=11.3Hz,0.7H),4.86(d,J=11.1Hz,1H),3.95(s,3H),1.57(s,3H),1.30(s,6H). 13 C NMR(101MHz,Chloroform-d)δ193.3,166.0,135.1,133.0,131.1,130.6,129.6, 124.6,123.6,116.2,115.3,82.9,62.9,52.6,34.5,28.4,28.1.HRMS(ESI)calcd for[C23H22N5O5+Na] + :429.1421,found:429.1424.

[0062] Example 12: Compound 12 (Formula I, R 1 =Cyano, R 2 =4-methylbenzoyl, R 3 = tert-butyloxycarbonyl, R 4 =5-bromo) preparation.

[0063]

[0064] N-Boc-3-cyano-5-bromoindole (0.2mmol, 64mg), 4-methylbenzaldehyde (0.26mmol, 31μL), photocatalyst TBADT (0.004mmol, 13mg) and 2mL MeCN / DCM (v / v, 1 / 1) were added to a 10ml dry Schlenk tube in sequence. The mixture was degassed and filled with nitrogen, and the reaction solution was pumped into a serpentine reactor. The reaction solution was irradiated with a 30W purple lamp for 24 hours. After the reaction was completed, it was concentrated on a rotary evaporator and then separated by column chromatography to obtain 50mg of colorless oily compound 11 with a yield of 62%. 1 HNMR(400MHz,Chloroform-d)δ8.02–7.84(m,3H),7.52–7.42(m,2H),7.35(d,J=7.8Hz,2H),6.09(d,J=1 1.0Hz, 0.3H), 5.97 (d, J = 11.1Hz, 0.7H), 4.82 (d, J = 10.9Hz, 1H), 2.47 (s, 3H), 1.59 (s, 3H), 1.32 (s, 6H). 13 C NMR(101MHz,Chloroform-d)δ192.8,145.8,142.1,133.4,132.4,130.0,129.1,128.8,127.8, 127.5,124.6,116.6,115.6,115.5,83.0,62.7,62.4,34.2,28.4,28.0,22.0.HRMS(ESI)calcd for[C22H21BrN2O3+Na] + :463.0628,found:463.0631.

[0065] Example 13: Compound 13 (Formula I, R 1 =Cyano, R 2 =propionyl,R 3 = tert-butyloxycarbonyl, R 4 =H) preparation.

[0066]

[0067] N-Boc-3-cyanoindole (0.2mmol, 48mg), methyl 3-formylbenzoate (0.26mmol, 43mg), photocatalyst TBADT (0.004mmol, 13mg) and 2mL MeCN / DCM (v / v, 1 / 1) were added to a 10ml dry Schlenk tube in sequence. The mixture was degassed and filled with nitrogen, and the reaction solution was pumped into a serpentine reactor. The reaction solution was irradiated with a 30W purple lamp for 24 hours. After the reaction was completed, it was concentrated on a rotary evaporator and then separated by column chromatography to obtain 39mg of colorless oily compound 13 with a yield of 63%. 1 H NMR(400MHz,Chloroform-d)δ7.92(s,0.6H),7.51(s,0.4H),7.33(d,J=7.5Hz,2H),7.07(t,J=7.5Hz,1H),5.04(t,J=16.9H z,1H),4.72(d,J=11.2Hz,1H),2.70(dq,J=18.7,7.1Hz,1H),2.48(s,br,1H),1.53(d,J=39.2Hz,9H),1.13(t,J=7.1Hz,3H). 13 C NMR(101MHz,Chloroform-d)δ205.2,150.7,142.3,130.5,124.9,124.6,123.7,123.6,116.5 ,115.3,83.6,82.9,67.3,66.7,33.9,33.0,28.3,7.0.HRMS(ESI)calcdfor[C17H20N2O3+Na] + :323.1366,found:323.1364.

[0068] Example 14: Compound 14 (Formula I, R 1 =Cyano, R 2 =phenylpropionyl, R 3 = tert-butyloxycarbonyl, R 4 =H) preparation.

[0069]

[0070] N-Boc-3-cyanoindole (0.2mmol, 48mg), hydrocinnamaldehyde (0.26mmol, 35mg), photocatalyst TBADT (0.004mmol, 13mg) and 2mL MeCN / DCM (v / v, 1 / 1) were added to a 10ml dry Schlenk tube in sequence. The mixture was degassed and filled with nitrogen, and the reaction solution was pumped into a serpentine reactor. The reaction solution was irradiated with a 30W purple lamp for 24 hours. After the reaction was completed, it was concentrated on a rotary evaporator and then separated by column chromatography to obtain 44mg of colorless oily compound 14 with a yield of 59%. 1 H NMR(400MHz,Chloroform-d)δ7.83(s,1H),7.41(s,0H),7.28–7.21(m,2H),7.21–7.15(m,2H),7.13–7.07(m,3H),6.98(t ,J=7.5Hz,1H),5.01(s,0H),4.91(d,J=9.8Hz,1H),4.62(d,J=11.3Hz,1H),2.97–2.60(m,4H),1.50(s,3H),1.35(s,6H). 13 C NMR(101MHz,Chloroform-d)δ203.8,152.2,150.6,142.1,140.6,130.5,128.6,128.5,126.3,124.9,124. 6,123.7,122.5,116.5,115.3,83.7,83.0,67.2,66.8,42.2,41.7,33.9,33.0,28.9,28.2.HRMS(ESI)calcd for[C23H24N2O3+Na] + :399.1679,found:399.1679.

[0071] Example 15: Compound 15 (Formula I, R 1 =Cyano, R 2 =phenylpropionyl, R 3 = tert-butyloxycarbonyl, R 4 =H) preparation.

[0072]

[0073] N-Boc-3-cyanoindole (0.2mmol, 48mg), hexanal (0.26mmol, 26mg), photocatalyst TBADT (0.004mmol, 13mg) and 2mL MeCN / DCM (v / v, 1 / 1) were added to a 10ml dry Schlenk tube in sequence. The mixture was degassed and filled with nitrogen, and the reaction solution was pumped into a serpentine reactor. The reaction solution was irradiated with a 30W purple lamp for 24 hours. After the reaction was completed, it was concentrated on a rotary evaporator and then separated by column chromatography to obtain 46mg of colorless oily compound 15 with a yield of 67%. 1 H NMR(400MHz,Chloroform-d)δ7.85(s,br,1H),7.25(t,J=7.1Hz,2H),6.99(t,J=7.6Hz,1H),5.00–4.93(m ,1H),4.63(d,J=11.3Hz,1H),2.62–2.54(m,1H),2.39(s,br,1H),1.70–1.10(m,15H),0.89–0.72(m,3H). 13 C NMR(101MHz,Chloroform-d)δ204.7,150.8,142.3,130.5,124.6,123.7,116.4,115.3, 83.0,67.2,39.6.33.9,31.5,31.3,30.4,30.3,29.8,28.3,22.5,13.9.HRMS(ESI)calcd for[C20H26N2O3+Na] + :365.1836,found:365.1837.

[0074] Example 16: Compound 16 (Formula I, R 1 =Cyano, R 2 = cyclohexylcarboxylic acid, R 3 = tert-butyloxycarbonyl, R 4 =H) preparation.

[0075]

[0076] N-Boc-3-cyanoindole (0.2mmol, 48mg), cyclohexylcarboxaldehyde (0.26mmol, 29mg) and photocatalyst TBADT (0.004mmol, 13mg) and 2mL MeCN / DCM (v / v, 1 / 1) were added to a 10ml dry Schlenk tube in sequence. The mixture was degassed and filled with nitrogen, and the reaction solution was pumped into a serpentine reactor. The reaction solution was irradiated with a 30W purple lamp for 24 hours. After the reaction was completed, it was concentrated on a rotary evaporator and then separated by column chromatography to obtain 45mg of colorless oily compound 16 with a yield of 64%. 1 H NMR (400MHz, Chloroform-d) δ7.94 (s, 0.5H), 7.48 (s, 0.5H), 7.31 (d, J = 7.4Hz, 2H), 7.05 (t, J = 7.2Hz, 1H), 5.2 4(d,J=38.0Hz,1H),4.71(s,1H),2.78–2.60(m,1H),2.20–1.77(m,4H),1.70–1.48(m,11H),1.34–1.20(m,4H). 13 C NMR(100MHz,Chloroform-d)δ206.65,150.9,12.4,130.4,124.4,123.6,116.8,115.5,83.0,66.1,65.1,29.4,28.4,27.3,26.0,25.8,25.5.HRMS(ESI)calcd for[C21H26N2O3+Na] + :377.1836,found:377.1838.

[0077] Example 17: Compound 17 (Formula I, R 1 =Cyano, R 2 =isobutyryl, R 3 = tert-butyloxycarbonyl, R 4 =H) preparation.

[0078]

[0079] N-Boc-3-cyanoindole (0.2mmol, 48mg), isobutylaldehyde (0.26mmol, 19mg), photocatalyst TBADT (0.004mmol, 13mg) and 2mL MeCN / DCM (v / v, 1 / 1) were added to a 10ml dry Schlenk tube in sequence. The mixture was degassed and filled with nitrogen, and the reaction solution was pumped into a serpentine reactor. The reaction solution was irradiated with a 30W purple lamp for 24 hours. After the reaction was completed, it was concentrated on a rotary evaporator and then separated by column chromatography to obtain 41mg of colorless oily compound 17 with a yield of 65%. 1 H NMR(400MHz,Chloroform-d)δ7.94(s,0.5H),7.50(s,0.5H),7.33–7.28(d,J=7.5Hz,2H),7.06(t,J=7.1 Hz,1H),5.25(s,br,1H),4.73(s,br,1H),2.98–2.91(m,1H),1.52–1.51(s,s,9H),1.21(d,J=6.7Hz,6H). 13 C NMR(101MHz,Chloroform-d)δ207.6,150.9,142.5,130.4,124.7,124.3,123.7,123.4,116.8,115 .7,115.2,83.4,83.0,66.2,65.2,39.5,38.4,34.3,33.2,28.4,19.1,17.5,17.2.HRMS(ESI)calcd for[C18H22N2O3+Na] + :337.1523,found:337.1525.

[0080] Example 18: Compound 18 (Formula I, R 1 =Cyano, R 2 =4-Benzyloxybenzoyl, R 3 = tert-butyloxycarbonyl, R 4 =H) preparation.

[0081]

[0082] N-Boc-3-cyanoindole (0.2mmol, 48mg), 4-benzyloxybenzaldehyde (0.26mmol, 55mg) and photocatalyst TBADT (0.004mmol, 13mg) and 2mL MeCN / DCM (v / v, 1 / 1) were added to a 10ml dry Schlenk tube in sequence. The mixture was degassed and filled with nitrogen, and the reaction solution was pumped into a serpentine reactor. The reaction solution was irradiated with a 30W purple lamp for 24 hours. After the reaction was completed, it was concentrated on a rotary evaporator and then separated by column chromatography to obtain 36mg of colorless oily compound 18 with a yield of 40%. 1 HNMR(400MHz,Chloroform-d)δ8.00(s,2H),7.51–7.28(m,8H),7.10–7.03(m,3H),5.98 (dd,J=57.4,9.9Hz,1H),5.14(s,2H),4.81(d,J=11.1Hz,1H),1.58(s,3H),1.31(s,6H). 13 C NMR(101MHz,Chloroform-d)δ192.0,163.6,150.7,142.8,135.9,131.3,131.1,130.5,128.8,128.5,127.7 ,124.5,123.4,116.3,115.2,115.2,83.4,82.6,70.4,62.5,62.1,34.6,34.1,28.4,28.1.HRMS(ESI)calcd for[C28H26N2O4+Na] + :477.1785,found:477.1787.

[0083] Example 19: Compound 19 (Formula I, R 1 =Cyano, R 2 =4-acetoxybenzoyl, R 3 = tert-butyloxycarbonyl, R 4 =H) preparation.

[0084]

[0085] N-Boc-3-cyanoindole (0.2mmol, 48mg), 4-acetoxybenzaldehyde (0.26mmol, 43mg) and photocatalyst TBADT (0.004mmol, 13mg) and 2mL MeCN / DCM (v / v, 1 / 1) were added to a 10ml dry Schlenk tube in sequence. The mixture was degassed and filled with nitrogen, and the reaction solution was pumped into a serpentine reactor. The reaction solution was irradiated with a 30W purple lamp for 24 hours. After the reaction was completed, it was concentrated on a rotary evaporator and then separated by column chromatography to obtain 34mg of colorless oily compound 19 with a yield of 42%. 1 H NMR(400MHz,Chloroform-d)δ8.03(s,3H),7.55–7.04(m,4H),7.06(t,J=7.5Hz,1H),5.9 6(dd,J=43.1,9.3Hz,1H),4.81(d,J=10.2Hz,1H),2.32(s,3H),1.56(s,3H),1.30(s,6H). 13 C NMR(101MHz,Chloroform-d)δ192.8,168.6,155.3,150.6,142.7,133.0,132.6,130.5,130.3,124.8,124.6 ,123.5,122.6,122.3,116.2,115.2,83.7,82.8,62.9,62.5,34.5,33.9,28.3,28.1,21.3.HRMS(ESI)calcd for[C23H22N2O5+Na] + :429.1421,found:429.1422.

[0086] Example 20: Compound 20 (Formula I, R 1 =Cyano, R 2 =N-methyl-N-formylaminomethyl, R 3 = tert-butyloxycarbonyl, R 4 =H) preparation.

[0087]

[0088] N-Boc-3-cyanoindole (0.2mmol, 48mg), DMF (0.4mmol, 29mg), photocatalyst TBADT (0.004mmol, 13mg) and 2mL MeCN / DCM (v / v, 1 / 1) were added to a 10ml dry Schlenk tube in sequence. The mixture was degassed and filled with nitrogen, and the reaction solution was pumped into a serpentine reactor. The reaction solution was irradiated with a 30W purple lamp for 24 hours. After the reaction was completed, it was concentrated on a rotary evaporator and then separated by column chromatography to obtain 41mg of colorless oily compound 20 with a yield of 65%. 1 H NMR(400MHz,Chloroform-d)δ7.95-7.80(s,s,1H),7.56(s,br,1H),7.34–7.23(m,2H),7.34–7.23(m,1H),5.10–5.04(m,0.4H),4.85(s,br,0.6H), 4.59(d,J=8.4Hz,0.6H), 4.52(d,J=8.3Hz,0.4H), 3.56(dd,J=14.7,4.0Hz ,1H),3.44–3.38(m,1H),2.94(s,1H),2.87(s,2H),1.47(d,J=2.1Hz,9H). 13 C NMR(101MHz,Chloroform-d)δ163.4,162.9,151.5,140.3,130.2,130.0,124.5,124.3,124.3, 124.3,124.0,117.1,117.0,116.6,116.5,83.1,82.4,50.1,45.6,31.1,28.2.HRMS(ESI)calcd for[C17H21N3O3+Na] + :338.1476,found:338.1477.

[0089] Example 21: Compound 21 (Formula I, R 1 =Methoxyacyl, R 2 =4-methylbenzoyl, R 3 = tert-butyloxycarbonyl, R 4 =H) preparation.

[0090]

[0091] N-Boc-3-methoxyindole (0.2mmol, 55mg), p-methylbenzaldehyde (0.26mmol, 31ul), photocatalyst TBADT (0.004mmol, 13mg) and 2mL MeCN / DCM (v / v, 1 / 1) were added to a 10ml dry Schlenk tube in sequence. The mixture was degassed and filled with nitrogen, and the reaction solution was pumped into a serpentine reactor. The reaction solution was irradiated with a 30W purple lamp for 24 hours. After the reaction was completed, it was concentrated on a rotary evaporator and then separated by column chromatography to obtain 40mg of colorless oily compound 21 with a yield of 50%. 1 H NMR(400MHz,Chloroform-d)δ7.99(d,J=8.2Hz,1H),7.83(d,J=6.0Hz,2H),7.29–7.81(m,4H),7.19(d,J=7.6Hz,1H),7.00(t,J=7.4H z,1H),6.04(d,J=6.4Hz,0.3H),5.89(d,J=11.4Hz,1H),4.80(d,J=11.3Hz,1H),3.32(s,3H),2.41(s,3H),1.57(s,3H),1.27(s,6H). 13 C NMR(101MHz,Chloroform-d)δ195.2,169.9,151.2,144.2,133.5,130.3,129.4,129.3,129.3 ,128.5,124.8,122.9,115.0,81.9,64.4,64.0,52.2,50.6,28.4,28.1,21.8.HRMS(ESI)calcd for[C17H21N3O3+Na] + :418.1625,found:418.1626.

[0092] Example 22: Compound 22 (Formula I, R 1 =Cyano, R 2 =4-methylbenzoyl, R 3 =Benzoyl, R 4 =H) preparation.

[0093]

[0094] N-Bz-3-cyanoindole (0.2mmol, 49mg), p-methylbenzaldehyde (0.26mmol, 31ul), photocatalyst TBADT (0.004mmol, 13mg) and 2mL MeCN / DCM (v / v, 1 / 1) were added to a 10ml dry Schlenk tube in sequence. The mixture was degassed and filled with nitrogen, and the reaction solution was pumped into a serpentine reactor. The reaction solution was irradiated with a 30W purple lamp for 24 hours. After the reaction was completed, it was concentrated on a rotary evaporator and then separated by column chromatography to obtain 45mg of colorless oily compound 22 with a yield of 61%. 1 H NMR (400MHz, Chloroform-d) δ8.03(d,J=8.1Hz,0.7H),7.94(d,J=8.2Hz,2H),7.78(d,J=8.2Hz,0.3H),7.42–7.29(m,6H),7.18(dt,J=25.3,7.7 Hz, 2H), 6.99 (d, J = 8.2Hz, 1H), 6.24 (d, J = 11.2Hz, 0.7H), 6.17 (d, J = 10.8Hz, 0.3H), 4.95 (d, J = 11.2Hz, 1H), 4.89 (d, J = 11.2Hz, 1H), 2.43 (s, 3H). 13 C NMR(101MHz,Chloroform-d)δ192.6,150.2,150.1,145.9,142.1,132.3,130.7,130.1,129.9,129.6,129.5,129.1,129. 0,126.3,126.2,125.1,124.6,124.4,123.0,121.6,121.5,116.0,115.6,62.9,62.6,35.0,34.2,22.0.HRMS(ESI)calcd for[C24H18N2O2+Na] + :389.1260,found:389.1262.

[0095] Example 23: Compound 23 (Formula I, R 1 =Cyano, R 2 =4-methylbenzoyl, R 3 =Benzyloxyacyl, R 4 =H) preparation.

[0096]

[0097] N-Cbz-3-cyanoindole (0.2mmol, 55mg), p-methylbenzaldehyde (0.26mmol, 31ul), photocatalyst TBADT (0.004mmol, 13mg) and 2mL MeCN / DCM (v / v, 1 / 1) were added to a 10ml dry Schlenk tube in sequence. The mixture was degassed and filled with nitrogen, and the reaction solution was pumped into a serpentine reactor. The reaction solution was irradiated with a 30W purple lamp for 24 hours. After the reaction was completed, it was concentrated on a rotary evaporator and then separated by column chromatography to obtain 53mg of colorless oily compound 23 with a yield of 67%. 1 H NMR(400MHz,Chloroform-d)δ8.03(d,J=8.1Hz,1H),7.95(d,J=6.9Hz,1H),7.80(d,J=8.0Hz,1H),7.41–7.16(m,8H),7.09(d,J=7.1Hz ,2H),6.11(d,J=11.0Hz,0.3H),6.00(d,J=11.1Hz,0.7H),5.37–5.26(m,1H),5.15–5.03(m,1H),4.83(d,J=11.1Hz,1H),2.44(s,3H). 13 C NMR(101MHz,Chloroform-d)δ192.9,153.1,151.4,145.6,142.4,141.1,135.4,135.1,132.6,132.3,130.5,129.8,129.1,128.9,128 .8,128.7,128.5,128.3,128.2,124.9,124.5,123.9,122.8,116.1,115.3,68.8,68.0,62.5,62.3,34.8,34.1,22.0.HRMS(ESI)calcd for[C25H20N2O3+Na] + :419.1367,found:419.1368.

[0098] Example 24: Compound 24 (Formula I, R 1 =Methoxyacyl, R 2 =3,4-dibenzyloxybenzoyl, R 3 = tert-butyloxycarbonyl, R 4 =H) preparation.

[0099]

[0100]

[0101] N-Boc-3-methoxyindole (0.2mmol, 55mg), 3,4-dibenzyloxybenzaldehyde (0.26mmol, 83mg), photocatalyst TBADT (0.004mmol, 13mg) and 2mL MeCN / DCM (v / v, 1 / 1) were added to a 10ml dry Schlenk tube in sequence. The mixture was degassed and filled with nitrogen, and the reaction solution was pumped into a serpentine reactor. The reaction solution was irradiated with a 30W purple lamp for 24 hours. After the reaction was completed, it was concentrated on a rotary evaporator and then separated by column chromatography to obtain 47mg of colorless oily compound 24 with a yield of 40%. 1 H NMR (400MHz, Chloroform-d) δ7.61–7.27(m,14H),7.18(d,J=7.5Hz,1H),7.01(t,J=7.0Hz,1H),6.94(d,J=8.4Hz,1H),5.99(d,J=11.3Hz,0. 3H),5.77(d,J=11.5Hz,0.7H),5.25(s,2H),5.23–5.10(m,2H),4.75(d,J=11.6Hz,1H),3.20(s,2H),3.10(s,1H),1.57(s,3H),1.22(s,6H). 13 C NMR(101MHz,Chloroform-d)δ194.0,169.9,153.2,151.1,148.4,143.2,142.3,136.8,136.4,129.3,129.0,128.7,128.6,128.2, 128.0,127.4,127.2,126.4,125.1,124.9,123.0,122.9,115.0,113.8,112.8,70.8,64.5,52.2,50.6,28.4,28.0.HRMS(ESI)calcd for[C36H35NO7+Na] + :616.2306,found:616.2307.

[0102] Example 25: Compound 25 (Formula I, R 1 =Cyano, R 2 =4-methylbenzoyl, R 3 =Acetyl, R 4 =H) preparation.

[0103]

[0104] N-Ac-3-cyanoindole (0.2mmol, 37mg), p-methylbenzaldehyde (0.26mmol, 31ul), photocatalyst TBADT (0.004mmol, 13mg) and 2mL MeCN / DCM (v / v, 1 / 1) were added to a 10ml dry Schlenk tube in sequence. The mixture was degassed and filled with nitrogen, and the reaction solution was pumped into a serpentine reactor. The reaction solution was irradiated with a 30W purple lamp for 24 hours. After the reaction was completed, it was concentrated on a rotary evaporator and then separated by column chromatography to obtain 32mg of colorless oily compound 25 with a yield of 52%. 1 H NMR(400MHz,Chloroform-d)δ7.95(d,J=8.1Hz,2H),7.44–7.27(m,5H),7.14(t,J=7.5Hz,1H),6.31(d,J=10.7Hz,0.7 H), 6.02 (d, J = 10.3Hz, 0.3H), 4.96 (d, J = 9.6Hz, 0.3H), 4.78 (d, J = 10.5Hz, 0.7H), 2.46 (d, J = 20.3Hz, 5H), 2.00 (s, 1H). 13 CNMR(101MHz,Chloroform-d)δ192.7,168.1,145.5,141.3,132.6,130.4,130.2,129.8,129.1,125.7 ,124.7,124.3,117.6,116.3,114.1,63.8,62.6,35.8,33.5,29.8,24.5,24.1,22.0.HRMS(ESI)calcd for[C36H35NO7+Na] + :616.2306,found:616.2307.

[0105] Example 26: Compound 26 (Formula I, R 1 and R 2 As shown below, R 3 = tert-butyloxycarbonyl, R 4 =H) preparation.

[0106]

[0107] N-Boc-3-methoxyindole (0.2mmol, 55mg), N-methylformamide (0.4mmol, 24mg), photocatalyst TBADT (0.004mmol, 13mg) and 2mL MeCN / DCM (v / v, 1 / 1) were added to a 10ml dry Schlenk tube in sequence. The mixture was degassed and filled with nitrogen, and the reaction solution was pumped into a serpentine reactor. The reaction solution was irradiated with a 30W purple lamp for 24 hours. After the reaction was completed, it was concentrated on a rotary evaporator and then separated by column chromatography to obtain 52mg of colorless oily compound 26 with a yield of 86%. 1 H NMR(400MHz,Chloroform-d)δ7.80(s,br,1H),7.41(d,J=7.6Hz,1H),7.23(t,J=7.8Hz,1H ),6.98(t,J=7.9Hz,1H),5.30(s,br,1H),4.39(d,J=9.0Hz,1H),2.90(s,3H),1.55(s,9H). 13 C NMR(101MHz,Chloroform-d)δ174.7,174.2,151.7,141.8,129.8,125.0,123.6,116.0,82.4,60.8,46.6,28.2,25.2.HRMS(ESI)calcd for[C16H18N2O4+Na] + :325.1159,found:325.1160

[0108] Example 27: Compound 27 (Formula I, R 1 =Cyano, R 2 = Cyclohexyl, R 3 = tert-butyloxycarbonyl, R 4 =H) preparation.

[0109]

[0110] N-Boc-3-cyanoindole (0.2mmol, 48mg), cyclohexane (2.0mmol, 168mg), photocatalyst TBADT (0.004mmol, 13mg) and 2mL MeCN / DCM (v / v, 1 / 1) were added to a 10ml dry Schlenk tube in sequence. The mixture was degassed and filled with nitrogen, and the reaction solution was pumped into a serpentine reactor. The reaction solution was irradiated with a 30W purple lamp for 24 hours. After the reaction was completed, it was concentrated on a rotary evaporator and then separated by column chromatography to obtain 26mg of colorless oily compound 27 with a yield of 40%. 1H NMR(400MHz,Chloroform-d)δ7.59(s,br,1H),7.33(d,J=7.5Hz,1H),7.31–7.26(m,1H),7.06(t,J=7.5Hz, 1H),4.62(s,2H),1.96–1.87(m,1H),1.80–1.76(m,2H),1.56(s,9H),1.48–1.34(m,2H),1.30–0.95(m,6H). 13 C NMR(101MHz,Chloroform-d)δ152.5,142.3,129.5,126.7,123.8,123.4,117.9,116.6,82.0,64.7,42.7,35.9,30.9,28.5,27.4,26.5,26.2.HRMS(ESI)calcd for[C20H26N2O2+Na] + :349.1886,found:349.1886.

[0111] Example 28: Compound 28 (Formula I, R 1 =Cyano, R 2 =Benzothiophene-3-yl, R 3 = tert-butyloxycarbonyl, R 4 =H) preparation.

[0112]

[0113] N-Boc-3-cyanoindole (0.2mmol, 48mg), 3-formylbenzothiophene (0.26mmol, 42mg), photocatalyst TBADT (0.004mmol, 13mg) and 2mL MeCN / DCM (v / v, 1 / 1) were added to a 10ml dry Schlenk tube in sequence. The mixture was degassed and filled with nitrogen, and the reaction solution was pumped into a serpentine reactor. The reaction solution was irradiated with a 30W purple lamp for 24 hours. After the reaction was completed, it was concentrated on a rotary evaporator and then separated by column chromatography to obtain 44mg of colorless oily compound 28 with a yield of 55%. 1H NMR(400MHz,Chloroform-d)δ8.71(s,1H),8.53(s,0.4H),8.32(s,0.6H),8.03(s,1H),7.89(d,J=7.8Hz,1H),7.42(dt,J= 43.1,10.9Hz,4H),7.10(t,J=7.5Hz,1H),5.90(dd,J=72.7,8.4Hz,1H),4.86(d,J=10.3Hz,1H),1.58(s,3H),1.27(s,6H). 13 C NMR(101MHz,Chloroform-d)δ188.6,150.7,142.7,139.7,137.4,136.7,130.7,130.4,126.5,1 26.2,125.8,124.7,123.7,122.4,116.2,115.2,82.9,64.6,34.9,28.4,28.1.HRMS(ESI)calcd for[C23H20N2O3S+Na] + :427.1087,found:427.1088.

[0114] Example 29: Compound 29 (Formula I, R 1 =Cyano, R 2 =N-methylaminoacyl, R 3 = tert-butyloxycarbonyl, R 4 =H) preparation.

[0115]

[0116] N-Boc-3-cyanoindole (0.2mmol, 48mg), N-methylformamide (0.4mmol, 24mg), photocatalyst TBADT (0.004mmol, 13mg) and 2mL MeCN / DCM (v / v, 1 / 1) were added to a 10ml dry Schlenk tube in sequence. The mixture was degassed and filled with nitrogen, and the reaction solution was pumped into a serpentine reactor. The reaction solution was irradiated with a 30W purple lamp for 24 hours. After the reaction was completed, it was concentrated on a rotary evaporator and then separated by column chromatography to obtain 48mg of colorless oily compound 29 with a yield of 74%. 1H NMR(400MHz,Chloroform-d)δ7.55(s,br,1H),7.35(d,J=7.1Hz,1H),7.31(d,J=7.7Hz,1H),7.08( t,J=7.5Hz,1H),6.88(s,br,1H),5.09(s,1H),4.88(s,br,1H),2.82(d,J=4.8Hz,3H),1.59(s,9H). 13 C NMR(101MHz,Chloroform-d)δ168.6,153.1,130.1,127.3,125.3,124.4,118.8,116.5,84.0,65.0,32.8,28.4,26.7.HRMS(ESI)calcdfor[C16H19N3O3+Na] + :324.1319,found:324.1320.

[0117] Example 30: Compound 30 (Formula I, R 1 =Cyano, R 2 =4-acetoxymethyl, R 3 = tert-butyloxycarbonyl, R 4 =H) preparation.

[0118]

[0119] N-Boc-3-cyanoindole (0.2mmol, 48mg), 4-acetoxymethylbenzaldehyde (0.26mmol, 36mg), photocatalyst TBADT (0.004mmol, 13mg) and 2mL MeCN / DCM (v / v, 1 / 1) were added to a 10ml dry Schlenk tube in sequence. The mixture was degassed and filled with nitrogen, and the reaction solution was pumped into a serpentine reactor. The reaction solution was irradiated with a 30W purple lamp for 24 hours. After the reaction was completed, it was concentrated on a rotary evaporator and then separated by column chromatography to obtain 55mg of colorless oily compound 30 with a yield of 66%. 1 H NMR(400MHz,Chloroform-d)δ7.98(d,J=8.0Hz,2H),7.55–7.41(m,3H),7.35–7.30(m,2H),7.06(t,J=7.5Hz,1H),6.07(d ,J=11.1Hz,0.3H),5.92(d,J=11.3Hz,0.7H),5.17(s,2H),4.83(d,J=11.2Hz,1H),2.14(s,3H),1.56(s,2H),1.29(s,4H). 13C NMR(101MHz,Chloroform-d)δ193.4,170.7,150.6,142.7,142.5,135.0,134.7,130.5,130.4,129.0,128. 3,123.5,124.8,124.5,123.5,122.5,116.2,115.1,83.5,82.7,65.3,62.9,62.5,34.4,33.8,28.0,20.9.

[0120] The cytotoxicity of the compounds obtained in Examples 1 to 30 against colorectal cancer cell lines DLD1 and HCT116 and esophageal cancer cell lines KYSE450 was determined by MTT assay, and the results are shown in the following table. Among them, Example compounds 4 and 5 had the best activity, reaching 14 μM and 16 μM respectively.

[0121] From the data in Table 1, it can be seen that the cis-2,3-disubstituted indoline compounds of the present invention have different degrees of inhibitory activity on the three tumor cell lines. Among them, compounds 4 and 5 have the best activity against the tested tumor cell lines (IC 50 Compounds 4 and 5 can be used as lead compounds for further structural optimization, which is expected to further improve their anti-tumor activity.

[0122] Table 1 Antiproliferation activity of cis-2,3-disubstituted indoline compounds on cancer cells

[0123]

[0124]

[0125]

[0126]

[0127]

[0128]

[0129]

Claims

1. A cis-2,3-disubstituted indoline compound as shown in formula I, characterized in that The 2,3-disubstituted indoline compound having a cis configuration has the following general structural formula: Among them: R 1 For cyano, C 1-8 Alkanoyl, aroyl, sulfonyl, C 1-8 Alkoxyacyl, aryloxyacyl, aminoacyl, arylaminoacyl or C 1-8 Alkyl; R 2 C 1-8 Alkyl, C 1-8 Cycloalkyl, C 1-8 Alkanoyl, aroyl, substituted aroyl, sulfonyl, C 1-8 Alkoxyacyl, aryloxyacyl, aminoacyl, arylaminoacyl or C 1-8 Alkyl; R 3 C 1-8 Alkanoyl, aroyl, sulfonyl, C 1-8 Alkoxyacyl, aryloxyacyl, aminoacyl, arylaminoacyl or C 1-8 Alkyl; R 4 For hydrogen, deuterium, halogen, cyano, C 1-8 Alkyl, aryl, heteroaryl, C 1-8 Alkanoyl, aroyl, sulfonyl, C 1-8 Alkoxyacyl, aryloxyacyl, aminoacyl, arylaminoacyl or C 1-8 Alkyl.

2. The compound of formula I, its pharmaceutically acceptable salt or hydrolyzable ester according to claim 1, characterized in that: In the compound shown in formula I, there are substituents at the 2-position and the 3-position of indoline, and the two substituents are in relative cis positions.

3. The pharmaceutically acceptable salt of the cis-2,3-disubstituted indoline compound according to claim 1 comprises potassium salt, sodium salt, ammonium salt, magnesium salt, calcium salt or hydrochloride.

4. The compound of formula I and its pharmaceutically acceptable salt according to claim 1, characterized in that: In the compounds shown in Formula I, there are substituents at both the 2-position and the 3-position of indoline, and the two substituents are in relative cis positions, including but not limited to the following compounds: 。 5. The method for preparing the cis-2,3-disubstituted indoline compound according to claim 1-4, characterized in that The method comprises the following steps: Step 1: At room temperature, in a reaction tube, N,3-disubstituted indole (Formula II, 1.0 equivalent) and HR 2 (1.3 equivalents) and 2% mol of tetrabutylammonium decatungstate (TBADT) catalyst are dissolved in dichloromethane / acetonitrile (5 ml of mixed solvent is added for every 1 mmol of substrate; v / v, 1 / 1), and the air in the reaction tube is replaced with nitrogen or argon. The reaction solution is pumped into a serpentine reaction tube with a peristaltic pump in a nitrogen or argon atmosphere and irradiated with 40 watts of 390nm purple light for 24 hours. In this step, the solvent can also be acetonitrile, acetone, 1,2-dichloroethane, dichloromethane, chloroform, ethyl acetate, or a mixed solvent of two of them. In this step, the wavelength of the light used can be any wavelength or band from 365nm to 450nm. In this step, the reaction can also be carried out in a glass or quartz reaction tube, but the reaction efficiency will be reduced and obvious trans byproducts will be generated. Step 2: After the reaction is completed, the reaction solution is concentrated and separated by column chromatography to obtain the target compound 1-30.

6. A pharmaceutical composition, characterized in that It comprises the compound represented by formula I according to any one of claims 1 to 4, a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, excipient or other active drug.

7. Use of the compound of formula I according to any one of claims 1 to 4, a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 5 in the preparation of a drug for treating and / or preventing cancer.

8. The use according to claim 7, characterized in that The cancers include malignant melanoma, glioma, lung cancer, prostate cancer, breast cancer, myeloproliferative and lymphoproliferative diseases, gastric cancer, colorectal cancer, esophageal cancer, ovarian cancer, and cervical cancer.

Citation Information

Patent Citations

  • Preparation and application of trans-2, 3-diacyl indoline compound

    CN117342996A